Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

SCN5A inhibits pyraclofos. 1 / 1

| 1

➶

reach

"Mutations in the Na v 1.5-encoding SCN5A gene account for> 75% of BrS genotype positive cases, although the yield of SCN5A testing for clinical cases is only = ~ 25% to 30%.5 In the presence of the previously described changes in ion currents, particularly I Na reduction, the net repolarizing effect of I to during phase 1 is significantly enhanced, thus reducing cell voltage to values below those required to activate L-type Ca ++ channels."

30571503

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...